Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
Explore this paper's citation graph
Summary
The clinical activity of ALK/MET inhibitors in ALK-positive patients probably reflects ALK, but not MET, activity, while diffuse heterogeneity without evidence of focal ALK rearrangements reflects technique, not biology.
- Type
- dissertation
- Published
- 2010-11-09
- Cited by
- 341
- References
- 32
- Access
- Open access
- OpenAlex
- https://openalex.org/W21062932
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:16999232
Keywords
Humanities, Philosophy
References
- KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.
- EML4-ALK fusion lung cancer: a rare acquired event.
- Anaplastic lymphoma kinase: signalling in development and disease
- Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC
- Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer
- Gastrosplenic fistula from Hodgkin's lymphoma.
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
- Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
- The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS
- ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
- Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
- Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.
Cited by
- Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer
- Applications of array-CGH for lung cancer.
- Molecular biomarkers for lung adenocarcinoma
- ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
- Angiogenic markers as prognostic factors in non-small cell lung cancer (NSCLC)
- [Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
- Molecular Diagnostic Testing in Non-Small Cell Lung Cancer
- Hypertrophic Pulmonary Osteoarthropathy in Anaplastic Lymphoma Kinase (ALK)-positive Lung Cancer.
- Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non–Small Cell Lung Cancer
- Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage
- Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
- Discordance between anaplastic lymphoma kinase status in primary non‐small‐cell lung cancers and their corresponding metastases
- ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options
- Predictive biomarkers in diffuse gliomas and non-small cell lung cancer
- IHC、FISH和RT-PCR检测对EML4-ALK重排的一致性
- Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
- Analysis of clinicopathological features of the echinoderm microtubule‐associated protein‐like‐4‐anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non‐small‐cell lung cancer
- ALK inhibitors and advanced non-small cell lung cancer (review).
- Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
- Anaplastic Lymphoma Kinase Immunocytochemistry on Cell-Transferred Cytologic Smears of Lung Adenocarcinoma